CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bioxyne Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bioxyne Ltd
Suite 506, Level 5, 50 Clarence Street
Phone: +61 290788180p:+61 290788180 SYDNEY, NSW  2000  Australia Ticker: BXNBXN

Business Summary
Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board AnthonyHo 12/3/2012 10/30/2012
Chief Executive Officer, Managing Director, Director SamuelWatson 11/17/2023 5/19/2023
Chief Financial Officer, Chief Operating Officer, Company Secretary Guy A.Robertson 5/19/2023 9/1/2016
Director JasonHine 5/19/2023 5/19/2023

Business Names
Business Name
BXN
P.T. GAMAT UTAMA
VRI BioMedical Limited

General Information
Number of Employees: 16 (As of 6/30/2005)
Outstanding Shares: 1,901,645,398 (As of 12/31/2023)
Shareholders: 1,842
Stock Exchange: ASX
Fax Number: +61 290787661


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024